Developing and Paying for Gene Therapies- How to Measure Value?

Published May 24, 2017
Boston, MA—May 24, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted a session this morning at its 22nd Annual International Meeting in Boston, MA, USA that examined the issue of developing and paying for gene therapies. The session, Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? [IP18], was moderated by Bill Dreitlein, PharmD, Director of Pharmaceutical Policy, Institute for Clinical and Economic Review, Boston, MA, USA. Panelists included:
  • Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
  • John Watkins, PharmD, MPH, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA
  • Clark Paramore, MSPH, Head of Value Demonstration, BlueBird Bio, Cambridge, MA, USA
As gene therapies are projected to gain approvals in the United States this year, the issue of how to measure value for these innovative treatments has come front and center. Although gene therapies are potentially curative and target conditions with high unmet need, they are expected to have a high price once they come to market. This scenario is creating tension between manufactures seeking compensation for their innovation, payers struggling with affordability issues, and technology assessment organizations striving to measure value. Bill Dreitlein, PharmD presented opinions from a stakeholder forum supported by the Institute for Clinical and Economic Review (ICER) and moderated the discussion. Clark Paramore, MSPH provided a manufacturer's perspective, and John Watkins, PharmD, MPH offered a US payer's viewpoint. Adrian Towse, MA, MPhil delivered a European outlook where some gene therapies are already licensed and where the National Institute for Health and Care Excellence (NICE) recently completed a “mock appraisal” of a regenerative medicine. Additional information on the ISPOR 22nd Annual International Meeting can be found here. Released presentations from the conference can be found here. Interested parties can follow news at ISPOR’s press site and on social media using the conference hashtag #ISPORBoston.

###

  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×